Indivumed to Exhibit at Molecular Med Tri-Con in San Francisco, USA, February 11–16

Molecular Med Tri-Con 2018 is one of the world’s leading international events in the field of drug discovery, development, and diagnostics. Please visit us at booth 824 to explore our state-of-the-art services that can support your research and development projects. Meet our specialists to discuss our tools for immuno-oncology research, such as fluorescent multiplex IHC, digital-image analysis, as well as isolation and flow-cytometry analysis of tumor-infiltrating lymphocytes. You can also learn how we can support you with specimen collection, genomics, proteomics, immunophenotyping, and more! From basic research to clinical trials, we’re here to assist you.

Date:February 11–16
Location:The Moscone South Convention Center
747 Howard Street
San Francisco, CA 94103

Please visit us at booth 824

Dual IHC and Quantitative Image Analysis Evaluating Immune Tumor Microenvironments

It was our great pleasure to take part in the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting, held on November 8–12 in National Harbor, USA. Indivumed, in collaboration with OracleBio, presented a poster showcasing dual immunohistochemistry (IHC) and digital histopathology as one example of the powerful techniques we use to study tumor-infiltrating immune cells. We demonstrated that chromogenic dual IHC and digital quantification of CD3- and LAG-3-positive T cells in clinical samples serves as a useful tool for specific evaluation of immune cell relationships in the tumor microenvironment of NSCLC tissue.

Enter your details here to download the research study poster presentation.

Indivumed Launches Fluorescent Multiplex IHC

Toward meeting your research needs, Indivumed is pleased to announce we have complemented our high-quality immunohistochemistry (IHC) services by offering Fluorescent Multiplex IHC with Tyramide Signal Amplification. With this service, up to six targets of interest can be analyzed on one tissue section. Tyramide Signal Amplification ensures the highest sensitivity in fully automated multiplex staining, and whole-slide scans, including seven fluorescent layers, allow complex digital image analyses and long-term storage.

Request a quote


September 19, 2017

Indivumed and Helomics partner to unlock the power of cancer biospecimens for drug discovery and development

Indivumed GmbH (Indivumed) and Helomics® Corporation (Helomics) announce their intentions to collaborate to analyze human cancer biospecimens and annotated clinical data from consenting patients around the world, enabling cutting-edge basic and translational research in cancer.

Read More

August 02, 2017

MedStar Health Collaborates with Indivumed to Advance Precision Oncology Research

MedStar Health will collaborate with Indivumed to advance our understanding of the molecular basis of cancer through collection and analysis of biospecimens and clinical data, making possible new individualized diagnosis and treatment of cancer.

Read More

June 01, 2017

Indivumed and Intermed to form strategic alliance

Intermed invests in Indivumed in order to accelerate the expansion of Indivumed’s worldwide leading Cancer Database.

Read More

April 11, 2017

Mayor Olaf Scholz honors Hamburg as international medical research location

Hamburg's First Mayor, Olaf Scholz, and international guests from science and business honored Indivumed at its 15-year anniversary.

Read More